home / stock / cycc / cycc quote
Last: | $1.8015 |
---|---|
Change Percent: | -2.62% |
Open: | $1.89 |
Close: | $1.85 |
High: | $1.95 |
Low: | $1.7717 |
Volume: | 9,757 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.8015 | $1.89 | $1.85 | $1.95 | $1.7717 | 9,757 | 04-19-2024 |
$1.85 | $1.91 | $1.85 | $1.96 | $1.81 | 37,739 | 04-18-2024 |
$1.96 | $1.67 | $1.96 | $2.0899 | $1.67 | 115,080 | 04-17-2024 |
$1.67 | $1.52 | $1.67 | $1.72 | $1.52 | 48,891 | 04-16-2024 |
$1.57 | $1.76 | $1.57 | $1.84 | $1.57 | 38,778 | 04-15-2024 |
$1.76 | $1.91 | $1.76 | $1.91 | $1.76 | 29,512 | 04-12-2024 |
$1.94 | $2 | $1.94 | $2.05 | $1.91 | 24,158 | 04-11-2024 |
$2.05 | $2.09 | $2.05 | $2.11 | $1.95 | 38,282 | 04-10-2024 |
$2.11 | $2.07 | $2.11 | $2.13 | $2.07 | 5,730 | 04-09-2024 |
$2.11 | $2.05 | $2.11 | $2.1399 | $2.05 | 24,922 | 04-08-2024 |
$2.1 | $2.21 | $2.1 | $2.21 | $2.03 | 17,941 | 04-05-2024 |
$2.1927 | $2.13 | $2.1927 | $2.1927 | $2.12 | 3,799 | 04-04-2024 |
$2.19 | $2.1541 | $2.19 | $2.22 | $2.0712 | 21,579 | 04-03-2024 |
$2.12 | $2 | $2.12 | $2.1491 | $2 | 20,139 | 04-02-2024 |
$2.05 | $2.2 | $2.05 | $2.2311 | $2.0101 | 22,065 | 04-01-2024 |
$2.1099 | $1.99 | $2.1099 | $2.14 | $1.99 | 46,138 | 03-29-2024 |
$2.1099 | $1.99 | $2.1099 | $2.14 | $1.99 | 46,138 | 03-28-2024 |
$1.96 | $2.09 | $1.96 | $2.09 | $1.94 | 14,688 | 03-27-2024 |
$1.92 | $2.11 | $1.92 | $2.18 | $1.8201 | 107,917 | 03-26-2024 |
$2.14 | $2.14 | $2.14 | $2.2199 | $2.058 | 58,529 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Med...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...